Maryvonne Hiance specializes in nuclear science and served, for 14 years, as manager of neutron studies at FRAMATOME (Areva). Over a 20-year period, she held the position of General Manager at innovative biotechnology companies including SangStat Atlantic, DrugAbuse Sciences and TcLand. She also founded and served as General Manager of Strategic Ventures, a consulting company providing support to technological companies.
Maryvonne Hiance has been a member of the French Strategic Council for Innovation and has served as Advisor to the French SMEs and Industry Ministry.
In 2008, she co-founded and served as CEO for Effimune, a biotechnology company specialized in immune regulation with clinical applications in autoimmunity, transplantation and immunooncology. Since the merger of Effimune with OSE Pharma in 2016 until 2021, she was Director for Public Affairs of OSE immunotherapeutics. She is Vice Chairman of the Board since 2016 .
From 2016 to 2021, Maryvonne has been successively Chairwoman and Vice Chairwoman of France Biotech, the French Association of Life Sciences entrepreneurs.
Maryvonne Hiance holds an Engineering Degree from the Ecole Polytechnique Féminine (Paris) and a Nuclear Engineering Degree from Polytech Grenoble (formerly the Institut des Sciences et Techniques Grenoble).